About
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California. Address: 170 Harbor Way, South San Francisco, CA, United States, 94080
Company Website : http://www.akerotx.com
Address : 170 Harbor Way, South San Francisco, CA, United States, 94080
Employees : 16
Fiscal Year End : December
Currency:
USD
Country :
USA